Segment Information (Tables)

9 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31,
(in millions)	2020			2019
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	34,899		$	31,146
Nuclear and Precision Health Solutions	213			215
Pharmaceutical segment revenue	35,112			31,361
Medical distribution and products (3)	3,539			3,431
Cardinal Health at-Home Solutions	512			440
Medical segment revenue	4,051			3,871
Total segment revenue	39,163			35,232
Corporate (4)	(6		)	(4		)
Total revenue	$	39,157		$	35,228

	Nine Months Ended March 31,
(in millions)	2020			2019
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	103,612		$	95,888
Nuclear and Precision Health Solutions	642			628
Pharmaceutical segment revenue	104,254			96,516
Medical distribution and products (3)	10,483			10,339
Cardinal Health at-Home Solutions	1,508			1,339
Medical segment revenue	11,991			11,678
Total segment revenue	116,245			108,194
Corporate (4)	(12		)	(13		)
Total revenue	$	116,233		$	108,181

(1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."

(2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(4)

Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]

The following tables present revenue by geographic area:

	Three Months Ended March 31,
(in millions)	2020			2019
United States	$	38,073		$	34,230
International	1,090			1,002
Total segment revenue	39,163			35,232
Corporate (1)	(6		)	(4		)
Total revenue	$	39,157		$	35,228

	Nine Months Ended March 31,
(in millions)	2020			2019
United States	$	113,053		$	105,190
International	3,192			3,004
Total segment revenue	116,245			108,194
Corporate (1)	(12		)	(13		)
Total revenue	$	116,233		$	108,181

(1)

Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:

	Three Months Ended March 31,
(in millions)	2020			2019
Pharmaceutical	$	534		$	536
Medical	178			155
Total segment profit	712			691
Corporate	(150		)	(259		)
Total operating earnings	$	562		$	432

	Nine Months Ended March 31,
(in millions)	2020			2019
Pharmaceutical	$	1,394		$	1,388
Medical	543			479
Total segment profit	1,937			1,867
Corporate	(6,305		)	(115		)
Total operating earnings/(loss)	$	(4,368	)	$	1,752

Assets by Reportable Segment

The following table presents total assets for each reportable segment and Corporate at:

(in millions)	March 31, 2020		June 30, 2019
Pharmaceutical	$	22,508	$	22,446
Medical	15,445		15,284
Corporate	3,195		3,233
Total assets	$	41,148	$	40,963